Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT-114143 in abnormal uterine bleeding
NCT07169214Phase 1Recruiting
- Sponsor
- ScinnoHub Pharmaceutical
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BT-114143 in abnormal uterine bleeding (AUB) (4 arms), sponsored by ScinnoHub Pharmaceutical. Primary endpoint: Safety evaluation at 2 weeks. Started Oct 2024; status: recruiting.
02
Drugs
BT-114143
03
Conditions
abnormal uterine bleeding (AUB)
Beyond the preview
Go deeper on NCT07169214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169214.